Trump Negotiates Landmark Deal with Lilly, Novo Nordisk to Offer Obesity Drugs for $149

The Trump administration is close to a major deal with drugmakers Eli Lilly and Novo Nordisk. The focus is on cutting the cost of powerful weight-loss drugs. These drugs include Zepbound and Wegovy. The goal is to make the treatments much more affordable.

Sources familiar with the talks say the lowest doses could sell for just $149 a month. These prices would be available through the TrumpRx platform. The agreement is also expected to change Medicare and Medicaid rules. These programs would then cover the drugs specifically for weight loss. Currently, Medicare often covers them only for diabetes.

The drug companies, facing political pressure and the threat of tariffs, have committed to increasing U.S. manufacturing. The White House push is part of a broader strategy. It aims to lower prescription drug costs by aligning them with prices in other developed countries. This negotiation represents a major shift in U.S. health policy regarding these highly expensive and popular treatments.